Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytarabine + thiotepa
- Development stage
- Unknown
- Lead developer
- Adienne S.r.l. S.U.
- Modality
- Small Molecules
- Administration
- Intravenous, Intraventricular
01
Overview
Cytarabine + thiotepa is a chemotherapy combination used primarily for primary central nervous system lymphoma (PCNSL) and as part of conditioning regimens for stem cell transplantation. Cytarabine is a pyrimidine nucleoside analog that inhibits DNA synthesis, while thiotepa is an alkylating agent that cross-links DNA strands. Both drugs can penetrate the blood-brain barrier, making them effective for CNS malignancies. This combination is often used as part of the MATRix regimen (methotrexate, cytarabine, thiotepa, and rituximab) for PCNSL treatment.
02
Targets
DNA polymerase familyDNA
Beyond the preview
Go deeper on cytarabine + thiotepa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytarabine + thiotepa.